Related Experiment Video
Updated: Apr 26, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE,
Antonio Cuneo1, Monia Marchetti2, Giovanni Barosi3
1Section of Hematology, Department of Medical Sciences, University of Ferrara, Via Savonarola, 9, 44121 Ferrara, Italy.
Abstract:
By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab-bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

